期刊
CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S25-S32出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis362
关键词
-
资金
- Abbott Laboratories
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Genentech (Roche)
- Gilead Sciences
- Glaxo-SmithKline
- Janssen Therapeutics
- Merck Sharp Dohme
- OraSure Technologies
- Vertex Pharmaceuticals
- Viral Hepatitis Action Coalition of the CDC Foundation
Natural cross-protective immunity is induced after spontaneous clearance of primary hepatitis C virus (HCV) infection. Although this suggests that effective prophylactic vaccines against HCV are possible, there are still several areas that require further study. Current data indicate that, at best, vaccine-induced immunity may not completely prevent HCV infection but rather prevent persistence of the virus. However, this may be an acceptable goal, because chronic persistence of the virus is the main cause of pathogenesis and the development of serious liver conditions. Therapeutic vaccine development is also highly challenging; however, strategies have been pursued in combination with current or new treatments in an effort to reduce the costs and adverse effects associated with antiviral therapy. This review summarizes the current state of HCV vaccines and the challenges faced for future development and clinical trial design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据